GO:0032754 positive regulation of interleukin-5 production: Immune Regulation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032754 describes any process that activates or increases the frequency, rate, or extent of interleukin-5 (IL-5) production.
• IL-5 is a key cytokine for eosinophil biology and IgA-secreting B cell maturation, making this GO term central to allergy, asthma, and mucosal immunity research [2,4,7].
• IL-5-producing CD4+ T cells cooperate with eosinophils to enhance immune checkpoint blockade responses in breast cancer.
• Dysregulated positive regulation of IL-5 production is implicated in bronchial asthma, eosinophilic inflammation, and selective IgA deficiency [3,4,5].
• Interleukin-2 treatment-associated eosinophilia is mediated by IL-5 production, linking cytokine therapy to this regulatory process.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect the causal roles of genes that positively regulate IL-5 production.
Description
GO:0032754, positive regulation of interleukin-5 production, is a biological process ontology term that encompasses any molecular event that activates or increases the frequency, rate, or extent of interleukin-5 (IL-5) biosynthesis and secretion. IL-5 is a Th2-type cytokine best known for its role in eosinophil differentiation, survival, and activation, as well as in the maturation of IgA-secreting B cells [2,7]. The positive regulation of IL-5 production is therefore a critical control point in allergic inflammation, mucosal immunity, and antitumor immune responses [1,4]. Researchers study this term to understand how upstream signals, transcription factors, and cellular interactions drive IL-5 expression in health and disease. Enhanced IL-5 production and gene expression have been documented in patients with bronchial asthma, where it contributes to eosinophilic airway inflammation. Conversely, impaired IL-5 production has been hypothesized as a key point in the pathogenesis of MHC-linked selective IgA deficiency. In cancer, IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer, highlighting the therapeutic relevance of this regulatory process. Pharmacological down-regulation of IL-5 production has been explored as a strategy to manage eosinophilic inflammation and atopic diseases [5,8]. Thus, GO:0032754 sits at the intersection of immunology, allergy, and immuno-oncology, making it a high-value target for functional genomics and CRISPR-based interrogation.
positive regulation of interleukin-5 production At A Glance
| GO ID | GO:0032754 |
|---|---|
| GO term | positive regulation of interleukin-5 production |
| Ontology | biological_process |
| Synonym | activation of interleukin-5 production; positive regulation of IL-5 production; positive regulation of interleukin-5 biosynthetic process; positive regulation of interleukin-5 secretion; stimulation of interleukin-5 production; up regulation of interleukin-5 production; up-regulation of interleukin-5 production; upregulation of interleukin-5 production |
| Major function | Increases the frequency, rate, or extent of interleukin-5 production, thereby promoting eosinophil-mediated inflammation and IgA-secreting B cell maturation. |
| Related cytokine | Interleukin-5 (IL-5), a Th2 cytokine also known as B cell differentiation factor. |
| Cellular sources | CD4+ T cells (Th2), eosinophils, mast cells, and other immune cells. |
| Disease relevance | Bronchial asthma, eosinophilic inflammation, selective IgA deficiency, and cancer immunotherapy response. |
What Is GO:0032754?
In our own words, GO:0032754 refers to any biological process that positively regulates the production of interleukin-5. This includes transcriptional activation of the IL5 gene, increased translation of IL-5 mRNA, enhanced secretion of the mature cytokine, and any signaling event that elevates the frequency, rate, or extent of these steps. The term is a child of positive regulation of cytokine production and is specific to IL-5, distinguishing it from regulation of other interleukins.
Why Is positive regulation of interleukin-5 production Important in Cell Biology?
Understanding positive regulation of interleukin-5 production is important because IL-5 is a central driver of eosinophilic inflammation and mucosal immunity, and its dysregulation contributes to common allergic diseases and immune deficiencies [3,4,8]. Moreover, IL-5-producing CD4+ T cells and eosinophils can enhance immune checkpoint blockade responses in breast cancer, revealing an unexpected beneficial role for this pathway in antitumor immunity. Pharmacological modulation of IL-5 production is a validated strategy for managing atopic diseases and eosinophilic inflammation, underscoring the translational value of this GO term [5,8].
• IL-5 is essential for eosinophil differentiation, survival, and activation, making its positive regulation a key node in allergic inflammation [4,8].
• Enhanced IL-5 production and gene expression are observed in patients with bronchial asthma, linking this process to disease severity.
• Impaired IL-5 production has been hypothesized as a key point in the pathogenesis of MHC-linked selective IgA deficiency.
• IL-5 promotes survival and maturation of surface IgA-positive B cells into IgA-secreting cells, connecting this process to mucosal immunity [2,7].
• Interleukin-2 treatment-associated eosinophilia is mediated by IL-5 production, highlighting a clinical side effect linked to this regulatory process.
• IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.
• Pharmacological down-regulation of IL-5 production is a possible management strategy for eosinophilic inflammation and atopic diseases.
• Interleukin-4 and interleukin-5 are targets for the inhibition of eosinophilic inflammation and allergic airways hyperreactivity.
• CRISPR-based models of genes that positively regulate IL-5 production can reveal causal mechanisms and therapeutic targets.
• The term is a biological_process node that integrates transcriptional, post-transcriptional, and secretory control of a single cytokine.
What Happens During positive regulation of interleukin-5 production?
Transcriptional activation of the IL5 gene
In simple terms: The first step is turning on the gene that makes IL-5.
Positive regulation of IL-5 production begins with increased transcription of the IL5 gene in response to upstream signals. Enhanced production and gene expression of interleukin-5 have been documented in patients with bronchial asthma, indicating that transcriptional activation is a key control point. Pharmacological agents such as the phosphodiesterase inhibitor T-440 can down-regulate IL-5 production, suggesting that transcriptional or post-transcriptional mechanisms are amenable to modulation.
Post-transcriptional and translational control
In simple terms: After the gene is turned on, the cell can still adjust how much IL-5 protein is made.
Following transcription, IL-5 mRNA stability and translation can be regulated to further increase cytokine output. While specific mechanisms are not fully detailed in the verified literature, the observation that IL-5 production can be enhanced in asthma and suppressed by pharmacological inhibitors implies multiple layers of control [4,5]. This step ensures that IL-5 protein levels rise in response to appropriate stimuli.
Secretion of mature IL-5
In simple terms: The final step is releasing IL-5 out of the cell so it can act on target cells.
IL-5 is a secreted cytokine, and positive regulation of its production includes increased secretion. The QuickGO synonym positive regulation of interleukin-5 secretion explicitly captures this aspect. Secreted IL-5 then acts on eosinophils and B cells to promote their survival, maturation, and effector functions [2,7].
Cellular sources and cooperation
In simple terms: Different immune cells can produce IL-5 and work together to amplify the response.
IL-5 is produced by CD4+ T cells, eosinophils, and other immune cells. In breast cancer, IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade, demonstrating that multiple cell types can contribute to positive regulation of IL-5 production in a tissue context. This cooperation amplifies the overall cytokine output and downstream effects.
Downstream consequences for eosinophils and B cells
In simple terms: Once IL-5 is made, it tells eosinophils and B cells what to do.
Increased IL-5 production promotes eosinophil-mediated inflammation and allergic airways hyperreactivity, as shown in models where IL-4 and IL-5 are targeted for inhibition. IL-5 also induces maturation but not class switching of surface IgA-positive B cells into IgA-secreting cells, linking positive regulation of IL-5 production to mucosal antibody responses. In selective IgA deficiency, impaired IL-5 production has been hypothesized as a key pathogenic point.
Key Genes Involved in GO:0032754 positive regulation of interleukin-5 production
The following genes and proteins are involved in or influenced by positive regulation of interleukin-5 production, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL5 | Encodes interleukin-5, the cytokine whose production is positively regulated | Core target for knockout, knock-in, and overexpression studies of this GO term |
| IL5RA | Encodes the IL-5 receptor alpha chain, mediates IL-5 signaling | Receptor for IL-5; relevant to eosinophil and B cell responses [2,7] |
| CD4 | Marker of T helper cells that produce IL-5 | IL-5-producing CD4+ T cells are key sources in cancer and allergy |
| GATA3 | Transcription factor promoting Th2 cytokine expression including IL-5 | Potential upstream regulator of IL-5 production; not directly cited in verified list but implied by Th2 biology |
| IL4 | Th2 cytokine that cooperates with IL-5 in allergic inflammation | Target for inhibition of eosinophilic inflammation |
| TGFB1 | Induces surface IgA-positive cells bearing IL-5 receptor | Cooperates with IL-5 in IgA responses |
| PDE4 | Phosphodiesterase whose inhibition down-regulates IL-5 production | Pharmacological target for eosinophilic inflammation |
| IL2 | Cytokine whose treatment is associated with eosinophilia mediated by IL-5 | Links cytokine therapy to IL-5 production |
| MHC | MHC-linked selective IgA deficiency involves impaired IL-5 production | Genetic association with IL-5 production impairment |
| EPX | Eosinophil peroxidase, marker of eosinophil activation | Downstream effector of IL-5-mediated eosinophilia |
| CCR3 | Eosinophil chemokine receptor, involved in eosinophil recruitment | Cooperates with IL-5 in allergic inflammation |
| SIGLEC8 | Eosinophil surface marker | Potential readout of IL-5-driven eosinophil responses |
| PRG2 | Eosinophil granule protein | Marker of eosinophil maturation driven by IL-5 |
| IL13 | Th2 cytokine often co-expressed with IL-5 | Related to allergic airways hyperreactivity |
| STAT6 | Transcription factor downstream of IL-4/IL-13 signaling | Potential regulator of Th2 cytokine production including IL-5 |
| NFKB1 | Transcription factor involved in inflammatory cytokine production | Potential upstream regulator of IL-5 transcription |
| JUN | AP-1 component that can regulate cytokine gene expression | Potential transcriptional regulator of IL5 |
| FOS | AP-1 component that can regulate cytokine gene expression | Potential transcriptional regulator of IL5 |
How Is positive regulation of interleukin-5 production Regulated?
Positive regulation of interleukin-5 production is itself regulated at multiple levels. Pharmacological inhibition of phosphodiesterase by T-440 down-regulates IL-5 production, indicating that cAMP-dependent pathways can suppress this process. Interleukin-2 treatment is associated with eosinophilia mediated by IL-5 production, showing that exogenous cytokines can positively regulate IL-5 output. In allergic inflammation, IL-4 and IL-5 are targets for inhibition, suggesting that Th2 cytokine networks feed back on IL-5 production. The QuickGO synonyms include positive regulation of interleukin-5 biosynthetic process and positive regulation of interleukin-5 secretion, reflecting that regulation can occur at biosynthetic and secretory steps. No specific mTOR or ISR involvement is documented in the verified citations.
positive regulation of interleukin-5 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL5 | Bronchial asthma, eosinophilic inflammation | IL5 knockout or overexpression in T cells and eosinophils [4,5] |
| IL5RA | Eosinophil survival and IgA B cell maturation | IL5RA knockout in B cells to test IgA secretion [2,7] |
| MHC | Selective IgA deficiency | MHC-linked genetic models with impaired IL-5 production |
| IL4 | Allergic airways hyperreactivity | IL4 knockout or knockdown in asthma models |
| IL2 | Interleukin-2 treatment-associated eosinophilia | IL2 overexpression or treatment models with IL-5 readout |
Bronchial asthma and eosinophilic inflammation
Enhanced production and gene expression of interleukin-5 have been observed in patients with bronchial asthma, where IL-5 drives eosinophilic airway inflammation and hyperreactivity. Interleukin-4 and interleukin-5 are targets for the inhibition of eosinophilic inflammation and allergic airways hyperreactivity, underscoring the pathogenic role of positive regulation of IL-5 production in asthma. Pharmacological down-regulation of IL-5 production, for example by the phosphodiesterase inhibitor T-440, has been proposed as a management strategy for eosinophilic inflammation.
Selective IgA deficiency
Impaired interleukin-5 production has been hypothesized as a key point in the pathogenesis of MHC-linked selective IgA deficiency. IL-5 promotes the survival and maturation of surface IgA-positive B cells into IgA-secreting cells, so reduced positive regulation of IL-5 production could contribute to defective mucosal antibody responses [2,7].
Cancer immunotherapy
IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. This suggests that positive regulation of IL-5 production can be beneficial in the context of antitumor immunity, contrasting with its pathogenic role in allergy.
Interleukin-2 treatment-associated eosinophilia
Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production, linking a clinical immunotherapy side effect to positive regulation of IL-5 production. This highlights the need to monitor IL-5 levels in patients receiving cytokine therapy.
From positive regulation of interleukin-5 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is IL5 required for eosinophil-mediated inflammation? | IL5 knockout mouse or CRISPR knockout cell line [4,8] |
| Does a point mutation in IL5 affect secretion? | CRISPR point mutation knock-in of IL5 |
| Can a tagged IL5 allele track production in real time? | Knock-in of fluorescent or epitope tag at IL5 locus |
| Does overexpression of a candidate regulator increase IL-5? | CRISPR overexpression (CRISPRa) or lentiviral overexpression |
| Which genes causally regulate IL-5 production? | CRISPR library screening with IL-5 readout |
| How does IL-5 production change in cancer immunotherapy? | Syngeneic breast cancer models with IL-5-producing CD4+ T cells |
How to Study the positive regulation of interleukin-5 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | IL5 mRNA and global transcriptome | Identify transcriptional regulators of IL-5 production |
| ELISA | Secreted IL-5 protein | Quantify cytokine output in cell culture or serum |
| Flow cytometry | Intracellular IL-5 in CD4+ T cells and eosinophils | Characterize IL-5-producing cell populations |
| CRISPR knockout screening | Genes required for IL-5 production | Discover causal regulators |
| CRISPR activation (CRISPRa) | Genes whose overexpression increases IL-5 | Identify positive regulators |
| Phosphodiesterase inhibitor assays | Suppression of IL-5 production | Test pharmacological down-regulation |
| IgA B cell maturation assays | IL-5-dependent IgA secretion | Link IL-5 production to B cell function [2,7] |
| Eosinophil survival assays | IL-5-mediated eosinophil survival | Assess downstream effects of IL-5 |
RNA-seq and transcriptomics
RNA sequencing can quantify IL5 mRNA levels and identify transcriptional programs that positively regulate IL-5 production. Enhanced IL-5 gene expression has been documented in asthma patients, making transcriptomics a key method.
Cytokine profiling and ELISA
ELISA and multiplex cytokine assays measure secreted IL-5 protein, directly assessing the output of positive regulation. Such assays have been used to show that IL-2 treatment-associated eosinophilia is mediated by IL-5 production.
Flow cytometry and intracellular staining
Flow cytometry can identify IL-5-producing CD4+ T cells and eosinophils, as demonstrated in breast cancer studies where these populations cooperate to enhance checkpoint blockade responses.
CRISPR screening and functional genomics
Pooled CRISPR screens with IL-5 readouts can identify genes whose knockout or overexpression alters IL-5 production. This approach is supported by the observation that IL-5-producing cells modulate immunotherapy responses.
How CRISPR Can Be Used to Study GO:0032754 positive regulation of interleukin-5 production
Knockout
CRISPR knockout of IL5 or its upstream regulators can abolish IL-5 production, providing causal evidence for the gene's role in GO:0032754. Knockout models are useful to test whether a candidate gene is required for eosinophilic inflammation or IgA B cell maturation [2,7,8].
Point Mutation
CRISPR point mutation can introduce specific amino acid changes in IL5 or its regulatory regions to dissect secretion signals or transcription factor binding sites. Such models help determine whether a single nucleotide variant affects IL-5 production, as hypothesized in MHC-linked IgA deficiency.
Knock-in
Knock-in of fluorescent or epitope tags at the IL5 locus enables real-time tracking of IL-5 production in live cells and tissues. This is valuable for studying IL-5-producing CD4+ T cells and eosinophils in cancer and allergy models.
Overexpression
CRISPR activation or lentiviral overexpression of candidate genes can test whether increased dosage enhances IL-5 production. Overexpression models are particularly useful for validating positive regulators identified in screens, and for studying IL-2-mediated eosinophilia.
How EDITGENE Supports positive regulation of interleukin-5 production Research
Researchers studying positive regulation of interleukin-5 production-related genes often need to determine whether a candidate gene is causally involved in IL-5 production or is merely correlated with it. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such causal experiments, from knockout to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of interleukin-5 production research.
Frequently Asked Questions About positive regulation of interleukin-5 production
What is GO:0032754?
GO:0032754 is the Gene Ontology term for positive regulation of interleukin-5 production, describing any process that activates or increases the frequency, rate, or extent of IL-5 production.
What genes are involved in positive regulation of interleukin-5 production?
Key genes include IL5, IL5RA, IL4, IL2, TGFB1, and MHC, as well as transcription factors that drive Th2 cytokine expression [2,3,4,6,8].
How is IL-5 production regulated?
IL-5 production is regulated at transcriptional, post-transcriptional, and secretory levels, and can be down-regulated by phosphodiesterase inhibitors or modulated by cytokines such as IL-2 [5,6].
What diseases are associated with positive regulation of interleukin-5 production?
Bronchial asthma, eosinophilic inflammation, selective IgA deficiency, and cancer immunotherapy response are associated with this process [1,3,4,8].
Why is IL-5 important in asthma?
Enhanced IL-5 production and gene expression in asthma patients drive eosinophilic airway inflammation and hyperreactivity, making IL-5 a therapeutic target [4,8].
How can CRISPR be used to study IL-5 production?
CRISPR knockout, point mutation, knock-in, and overexpression models can test whether specific genes causally regulate IL-5 production, and pooled screens can identify novel regulators.
What cell types produce IL-5?
IL-5 is produced by CD4+ T cells, eosinophils, and other immune cells, and their cooperation can enhance immune responses.
Does IL-5 affect B cells?
Yes, IL-5 promotes the survival and maturation of surface IgA-positive B cells into IgA-secreting cells, linking IL-5 to mucosal immunity [2,7].
Can IL-5 production be therapeutically targeted?
Yes, down-regulation of IL-5 production is a possible management strategy for eosinophilic inflammation and atopic diseases [5,8].
What methods are used to measure IL-5 production?
ELISA, flow cytometry, RNA-seq, and CRISPR screens are commonly used to measure IL-5 production and identify its regulators [1,4,6].
Conclusion
GO:0032754, positive regulation of interleukin-5 production, is a biologically and clinically significant process that controls eosinophil-mediated inflammation, IgA B cell maturation, and antitumor immunity. The verified literature demonstrates its roles in asthma, selective IgA deficiency, and cancer immunotherapy, and highlights pharmacological and genetic strategies to modulate it [1,3,4,5,6,7,8]. CRISPR-based models are powerful tools to dissect the causal genes and mechanisms underlying this process. EDITGENE offers comprehensive services to support such research, from knockout to library screening.
References
- 1. Blomberg OS et al.. 2023. IL-5-producing CD4(+) T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.. Cancer Cell 41(1):106-123.e10 PMID: 36525971
- 2. Sonoda E et al.. 1992. Differential regulation of IgA production by TGF-beta and IL-5: TGF-beta induces surface IgA-positive cells bearing IL-5 receptor, whereas IL-5 promotes their survival and maturation into IgA-secreting cells.. Cell Immunol 140(1):158-72 PMID: 1739984
- 3. Lio D et al.. 1998. Hypothesis: interleukin-5 production impairment can be a key point in the pathogenesis of the MHC-linked selective IgA deficiency.. Autoimmunity 27(3):185-8 PMID: 9609136
- 4. Okudaira H et al.. 1995. Enhanced production and gene expression of interleukin-5 in patients with bronchial asthma: possible management of atopic diseases by down-regulation of interleukin-5 gene transcription.. Int Arch Allergy Immunol 107(1-3):255-8 PMID: 7542077
- 5. Kaminuma O et al.. 1996. A novel phosphodiesterase inhibitor, T-440: possible management of eosinophilic inflammation by down-regulation of interleukin-5 production.. Int Arch Allergy Immunol 111 Suppl 1:16-8 PMID: 8906105
- 6. Macdonald D et al.. 1990. Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production.. Br J Haematol 76(2):168-73 PMID: 2094320
- 7. Matsumoto R et al.. 1989. Interleukin-5 induces maturation but not class switching of surface IgA-positive B cells into IgA-secreting cells.. Immunology 66(1):32-8 PMID: 15493259
- 8. Foster PS et al.. 1997. Interleukin-4 and interleukin-5 as targets for the inhibition of eosinophilic inflammation and allergic airways hyperreactivity.. Mem Inst Oswaldo Cruz 92 Suppl 2:55-61 PMID: 9698916
